Want to see IN:VALIANTLAB full AI Analyst Report?
VALIANTLAB Stock Chart & Stats
₹73.50
-₹2.57(-2.33%)
At close: 4:00 PM EST
₹73.50
-₹2.57(-2.33%)
Day’s Range― - ―
52-Week Range₹47.60 - ₹99.31
Previous CloseN/A
Volume41.92K
Average Volume (3M)1.58K
Market Cap
₹3.27B
Enterprise Value₹4.01B
Total Cash (Recent Filing)₹331.50M
Total Debt (Recent Filing)₹462.12M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding54,312,500
10 Day Avg. Volume2,243
30 Day Avg. Volume1,577
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.39
P/FCF Ratio-6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
API Manufacturing Business ModelA focused API and bulk-drug manufacturing model provides durable B2B revenue streams from pharmaceutical customers. Specialized manufacturing capabilities and recurring supply contracts tend to produce steadier demand and longer customer relationships versus one-off retail sales.
Conservative Leverage / Solid Equity BaseA large equity cushion relative to modest debt provides financial flexibility to absorb cyclical pressures, fund capex or R&D, and reduces near-term refinancing risk. This balance-sheet strength supports stability and strategic investment over the medium term.
FY2026 Revenue ReboundA material top-line recovery indicates improving demand or regained market share, giving management room to focus on margin restoration. Sustained revenue growth creates scale benefits that can support longer-term margin recovery if cost control follows.
Bears Say
Profitability DeteriorationDespite higher revenue, the company is not converting sales into healthy operating profits, implying margin compression, pricing pressure, or elevated operating costs. Persistent weak profitability undermines return on invested capital and limits internal reinvestment capacity.
Weak Cash Generation / Heavy Cash BurnConsistent negative operating and free cash flows signal reliance on external funding or asset sales to support operations and growth. This reduces resilience to shocks, constrains capex or debt paydown, and raises funding risk if adverse trends persist.
Earnings And ROE VolatilityLarge swings in profitability and ROE indicate business volatility or cyclicality and raise execution risk. Such inconsistency complicates long-term planning, makes forecasting cash flows harder, and can limit investor and creditor confidence in sustained performance.
Valiant Laboratories Ltd. News
VALIANTLAB FAQ
What was Valiant Laboratories Ltd.’s price range in the past 12 months?
Valiant Laboratories Ltd. lowest stock price was ₹47.60 and its highest was ₹99.31 in the past 12 months.
What is Valiant Laboratories Ltd.’s market cap?
Valiant Laboratories Ltd.’s market cap is ₹3.27B.
When is Valiant Laboratories Ltd.’s upcoming earnings report date?
Valiant Laboratories Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 11 days.
How were Valiant Laboratories Ltd.’s earnings last quarter?
Valiant Laboratories Ltd. released its earnings results on May 14, 2026. The company reported ₹0.32 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.32.
Is Valiant Laboratories Ltd. overvalued?
According to Wall Street analysts Valiant Laboratories Ltd.’s price is currently Overvalued.
Does Valiant Laboratories Ltd. pay dividends?
Valiant Laboratories Ltd. does not currently pay dividends.
What is Valiant Laboratories Ltd.’s EPS estimate?
Valiant Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valiant Laboratories Ltd. have?
Valiant Laboratories Ltd. has 54,312,500 shares outstanding.
What happened to Valiant Laboratories Ltd.’s price movement after its last earnings report?
Valiant Laboratories Ltd. reported an EPS of ₹0.32 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.028%.
Which hedge fund is a major shareholder of Valiant Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VALIANTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valiant Laboratories Ltd.
Valiant Laboratories Limited, an India-based company, specializes in the production of active pharmaceutical ingredients (APIs) and bulk drugs, serving both domestic and international markets. Its primary product is paracetamol, manufactured in various grades that meet Indian, British, European, and United States pharmacopoeia standards. This crucial compound is utilized in treatments for common ailments such as headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. Beyond pharmaceuticals, the company also supplies specialty chemicals. Originally established in 1980 and headquartered in Mumbai, India, the firm rebranded as Valiant Laboratories Limited in August 2021, having previously operated under the name Bharat Chemicals. It functions as a subsidiary of Dhanvallabh Ventures LLP.
Technical Analysis
Albert David Ltd
―
Bafna Pharmaceuticals Limited
―
Medicamen Biotech Limited
―
Medico Remedies Ltd.
―
Zim Laboratories Ltd.
―